argenx SE ARGX.BR Open argenx SE in new tab
argenx SE Analysis (ARGX.BR)
Is argenx SE a good investment? argenx SE (ARGX.BR) is currently trading at 647.20 EUR. Market analysts have a consensus price target of 841.21 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 38.32. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: argenx SE is expected to release its next earnings report on July 23, 2026. The market consensus estimate for Forward EPS is 30.95.
Investor FAQ
Does argenx SE pay a dividend?
No, it does not currently pay a dividend.
What asset class is argenx SE?
argenx SE is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 23, 2026. The company currently has a trailing EPS of 16.89.
Company Profile
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion